Novo Nordisk A/s

This study tests if a new insulin taken once a week (insulin icodec) controls blood sugar as well as a standard daily insulin (insulin glargine) in adults with type 1 diabetes. About 877 participants will use either weekly or daily insulin, plus rapid-acting insulin at meals, for…

This study tests a new medicine, NNC6019-0001, to see if it can lower the risk of heart-related death and hospital stays in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 1,280 adults with ATTR-CM will …

This study tests if a once-weekly insulin shot (icodec) works as well as daily insulin shots for controlling blood sugar in people with type 2 diabetes. About 586 adults who have never used insulin before will take either the weekly or a daily insulin for 13 months. The goal is t…

This study tests a new medicine called NNC0487-0111, given as a weekly shot, to see if it helps people with obesity lose weight safely. About 1,150 adults will receive either the active drug or a placebo (dummy shot) for several months. The main goal is to measure how much body w…

This early-stage study looks at whether combining two experimental weight-loss drugs (cagrilintide and NNC0480-0389) causes less nausea, vomiting, and diarrhea than taking cagrilintide alone. About 100 women with overweight or obesity will receive both combinations at different t…